(Q52892987)

9 May 2018

title

Omacetaxine mepesuccinate for the treatment of leukemia. (English)

1 reference

9 May 2018

main subject

(-)-homoharringtonine

1 reference

ChEBI release 2020-05-28

1 reference

Theo Daniel Kim

1

1 reference

9 May 2018

Mareike Frick

series ordinal

2

1 reference

9 May 2018

Philipp le Coutre

series ordinal

3

1 reference

9 May 2018

language of work or name

English

0 references

publication date

1 October 2011

1 reference

9 May 2018

Expert Opinion on Pharmacotherapy

published in

1 reference

9 May 2018

volume

12

1 reference

9 May 2018

issue

15

1 reference

9 May 2018

page(s)

2381-2392

1 reference

9 May 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Induction and postremission strategies in acute myeloid leukemia: what is new?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

"I am older, not elderly," said the patient with acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

From traditional Chinese medicine to rational cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Cephalotaxine esters: antileukemic advance or therapeutic failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Inhibition of Translation in Eukaryotic Systems by Harringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

U2504 Determines the Species Specificity of the A-Site Cleft Antibiotics:

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Cytotoxicity and cell cycle specificity of homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Inhibitory effects of omacetaxine on leukemic stem cells and BCR-ABL-induced chronic myeloid leukemia and acute lymphoblastic leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Homoharringtonine reduced Mcl-1 expression and induced apoptosis in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Altering chemosensitivity by modulating translation elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Homoharringtonine affects the JAK2-STAT5 signal pathway through alteration of protein tyrosine kinase phosphorylation in acute myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Central nervous system (CNS) penetration of homoharringtonine (HHT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Homoharringtonine--perspectives on an active new natural product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Homoharringtonine: history, current research, and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Low dose of homoharringtonine and cytarabine combined with granulocyte colony-stimulating factor priming on the outcome of relapsed or refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Therapeutic experience of adult acute myeloid leukemia in a single institution of China and its relationship with chromosome karyotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

A homoharringtonine-based induction regimen for the treatment of elderly patients with acute myeloid leukemia: a single center experience from China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Standard-dose imatinib plus low-dose homoharringtonine and granulocyte colony-stimulating factor is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis who have failed prior single-agent therapy with ima

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

The effect of homoharringtonine in patients with chronic myeloid leukemia who have failed or responded suboptimally to imatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

The durable clearance of the T315I BCR-ABL mutated clone in chronic phase chronic myelogenous leukemia patients on omacetaxine allows tyrosine kinase inhibitor rechallenge

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Effect of homoharringtonine on the viability of murine leukemia P388 cells resistant to either adriamycin, vincristine, or 1-beta-D-arabinofuranosylcytosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Modulation of drug resistance in homoharringtonine-resistant C-1300 neuroblastoma cells with cyclosporine A and dipyridamole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Sequential emergence of MRP- and MDR1-gene over-expression as well as MDR1-gene translocation in homoharringtonine-selected K562 human leukemia cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.613378

10.1517/14656566.2011.613378

21 January 2018

Identifiers

DOI

1 reference

9 May 2018

1 reference

9 May 2018